Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
United European Gastroenterol J
2023 Apr 01;113:271-281. doi: 10.1002/ueg2.12367.
Show Gene links
Show Anatomy links
Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG-IBD study.
Dragoni G
,
Castiglione F
,
Bezzio C
,
Pugliese D
,
Spagnuolo R
,
Viola A
,
Cocomazzi F
,
Aratari A
,
Savarino EV
,
Balestrieri P
,
Onali S
,
Viganò C
,
Ribaldone DG
,
Innocenti T
,
Testa A
,
Saibeni S
,
Privitera G
,
Milla M
,
Armuzzi A
,
Fantini MC
,
Fiorino G
.
???displayArticle.abstract???
BACKGROUND: The management of postoperative recurrence (POR) in Crohn's disease (CD) after ileo-colonic resection is a highly debated topic. Prophylactic immunosuppression after surgery is currently recommended in the presence of at least one clinical risk factor.
OBJECTIVE: Our aim was to determine whether early immunosuppression can be avoided and guided by endoscopy in CD patients with only one risk factor.
METHODS: CD patients with only one risk factor for POR, including previous intestinal resection, extensive small intestine resection (>50 cm), fistulising phenotype, history of perianal disease, and active smoking, were retrospectively included. Two groups were formed based on whether immunosuppression was started immediately after surgery ("prophylaxis group") or guided by endoscopy ("endoscopy-driven group"). Primary endpoints were rates of any endoscopic recurrence (Rutgeerts ≥ i2a) and severe endoscopic recurrence (i4) within 12 months after surgery. Secondary outcomes were clinical recurrence rates at 6, 12 and 24 months after surgery.
RESULTS: A total of 195 patients were enroled, of whom 61 (31.3%) received immunoprophylaxis. No differences between immunoprophylaxis and the endoscopy-driven approach were found regarding any endoscopic recurrence (36.1% vs. 45.5%, respectively, p = 0.10) and severe endoscopic recurrence (9.8% vs. 15.7%, respectively, p = 0.15) at the first endoscopic evaluation. Clinical recurrence rates were also not statistically different (p = 0.43, p = 0.09, and p = 0.63 at 6, 12, and 24 months, respectively).
CONCLUSIONS: In operated CD patients with only one risk factor for POR, immediate immunoprophylaxis does not decrease the rate of early clinical and endoscopic recurrence. Prospective studies are needed to confirm our results.
Adamina,
ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment.
2020, Pubmed
Adamina,
ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment.
2020,
Pubmed
Beelen,
Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn's Disease: A Pooled Analysis of 6 Trials.
2022,
Pubmed
Bernell,
Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn's disease.
2000,
Pubmed
Burr,
Systematic Review and Network Meta-Analysis of Medical Therapies to Prevent Recurrence of Post-Operative Crohn's Disease.
2019,
Pubmed
Dal Piaz,
Predictivity of early and late assessment for post-surgical recurrence of Crohn's disease: Data from a single-center retrospective series.
2021,
Pubmed
De Cruz,
Crohn's disease management after intestinal resection: a randomised trial.
2015,
Pubmed
Domènech,
Impact of azathioprine on the prevention of postoperative Crohn's disease recurrence: results of a prospective, observational, long-term follow-up study.
2008,
Pubmed
Dragoni,
The prevention and management of Crohn's disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 Survey.
2020,
Pubmed
Ferrante,
Systematic versus Endoscopy-driven Treatment with Azathioprine to Prevent Postoperative Ileal Crohn's Disease Recurrence.
2015,
Pubmed
Gionchetti,
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations.
2017,
Pubmed
Harvey,
A simple index of Crohn's-disease activity.
1980,
Pubmed
Joustra,
Benefit of Risk-stratified Prophylactic Treatment on Clinical Outcome in Postoperative Crohn's Disease.
2023,
Pubmed
Kalman,
Decrease in primary but not in secondary abdominal surgery for Crohn's disease: nationwide cohort study, 1990-2014.
2020,
Pubmed
Luglio,
Surgical Prevention of Anastomotic Recurrence by Excluding Mesentery in Crohn's Disease: The SuPREMe-CD Study - A Randomized Clinical Trial.
2020,
Pubmed
López-Sanromán,
Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised Trial.
2017,
Pubmed
McLeod,
Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial.
2009,
Pubmed
Pouillon,
Risk of Late Postoperative Recurrence of Crohn's Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple Centers.
2021,
Pubmed
Quezada,
Adverse events in IBD therapy: the 2018 update.
2018,
Pubmed
Regueiro,
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.
2016,
Pubmed
Riss,
Repeat intestinal resections increase the risk of recurrence of Crohn's disease.
2013,
Pubmed
Rutgeerts,
Predictability of the postoperative course of Crohn's disease.
1990,
Pubmed
Silverberg,
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.
2005,
Pubmed
Simillis,
A meta-analysis comparing incidence of recurrence and indication for reoperation after surgery for perforating versus nonperforating Crohn's disease.
2008,
Pubmed
To,
Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease.
2016,
Pubmed
Torres,
Crohn's disease.
2017,
Pubmed
Valibouze,
Post-surgical recurrence of Crohn's disease: Situational analysis and future prospects.
2021,
Pubmed
Yamada,
The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease.
2018,
Pubmed
Yanai,
Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study.
2022,
Pubmed
Zhao,
The Burden of Inflammatory Bowel Disease in Europe in 2020.
2021,
Pubmed
de Souza,
Immunopathogenesis of IBD: current state of the art.
2016,
Pubmed